1. What happened
Acquisition adds a substantial annotated pathology-slide dataset and AI technology. Company acquisition price is not a price paid solely for data; asset-specific rights need strict-qualification review. The announcement describes acquisition of the operating business and dataset; no independently priced data asset or uniform sublicensing right is inferred.
2. Buyer / seller
Tempus is the AI buyer or model-development side. Paige owns or contributes the proprietary corpus.
3. Economics
Whole-company consideration of $81.25 million, predominantly Tempus common stock, plus assumption of the remaining Azure commitment. No allocation to data alone. Economics scope: Whole-company consideration of $81.25 million, predominantly Tempus common stock, plus assumption of the remaining Azure commitment. No allocation to data alone.. Strategic Signal has not estimated undisclosed consideration.
4. Proprietary data
Paige's clinically annotated, de-identified pathology dataset of nearly seven million slides with associated clinical and molecular information, acquired with its AI applications. Historical depth: The exact licensed or transferred historical window is not disclosed.. Refreshability: Ongoing refresh obligations and the exact delivered corpus are not disclosed..
5. Rights and restrictions
Use is bounded by the announced agreement; full contractual controls are not disclosed. Ownership: permitted through the announced company acquisition; underlying third-party data rights remain subject to their terms. Training: not disclosed. Post-training: not disclosed.
6. Why the data matters for AI
Tempus intends to use the acquired pathology data and technology in oncology foundation-model development. The underlying dataset-specific training and sublicensing contract terms are not disclosed. No recipient-accessible repeated context/intervention/outcome structure is established by this announcement.
7. Asset Score — Pending/100
Only documented AI use and bounded rights usability are assessed. Evidence for remaining comparative corpus or transaction factors is insufficient; coverage remains below the locked 70% threshold and no total score is published. Score coverage: 14%.
| Factor | Weight | Rating / 5 | Points |
|---|---|---|---|
| Uniqueness / scarcity | 12 | Unknown | — |
| Historical depth | 8 | Unknown | — |
| Decision → outcome richness | 13 | Unknown | — |
| Decision Value Density | 13 | Unknown | — |
| Real-world grounding | 10 | Unknown | — |
| Domain economic value | 9 | Unknown | — |
| Refreshability | 8 | Unknown | — |
| Proprietary advantage | 9 | Unknown | — |
| Model-learning usefulness | 10 | 3.5 | 7.0 |
| Non-replicability | 4 | Unknown | — |
| Rights usability | 4 | 3 | 2.4 |
8. Transaction Signal Score — Pending/100
Only documented AI use and bounded rights usability are assessed. Evidence for remaining comparative corpus or transaction factors is insufficient; coverage remains below the locked 70% threshold and no total score is published. Score coverage: 26%.
| Factor | Weight | Rating / 5 | Points |
|---|---|---|---|
| Disclosed economics | 16 | Unknown | — |
| Clean price discovery | 16 | Unknown | — |
| Separability of data consideration | 15 | Unknown | — |
| Explicit training / model-improvement use | 14 | 3 | 8.4 |
| Clarity of rights purchased | 12 | 3 | 7.2 |
| Competing bids | 10 | Unknown | — |
| Strategic buyer quality | 6 | Unknown | — |
| Repeatability / precedent value | 6 | Unknown | — |
| Independent model-uplift evidence | 5 | Unknown | — |
9. M&A / valuation implications
Analysis: this is evidence of a governed external-asset arrangement, not a standalone valuation comparable without separable economics.
10. Evidence boundary
Strict qualification rests on the defined external corpus and separately material licensed, research or acquired rights, rather than ordinary internal AI deployment. Company acquisition price is not a price paid solely for data; asset-specific rights need strict-qualification review. The announcement describes acquisition of the operating business and dataset; no independently priced data asset or uniform sublicensing right is inferred. Rights not expressly established remain not_disclosed. This historical addition is not a new November announcement.